Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27480081 | 0.83 | TSHR (0.37) | TSHRALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL6685614 | 0.77 | ALDH1A1 (0.50) | TSHRALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL7395531 | 0.77 | CA1 (0.41) | TSHRALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL630704 | 0.77 | TSHR (0.44) | TSHRALDH1A1TDP1CHRM2CHRM4 | |
| SCHEMBL5200741 | 0.74 | TSHR (0.40) | TSHRALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL27480251 | 0.73 | ALDH1A1 (0.41) | TSHRALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL12314325 | 0.73 | TSHR (0.43) | TSHRALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL12314349 | 0.73 | TSHR (0.43) | TSHRALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL28786360 | 0.73 | TSHR (0.41) | TSHRALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL28837873 | 0.72 | TSHR (0.34) | TSHRALDH1A1LMNAHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159789-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| EP-2419413-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159789-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | DPYD, PGF, VEGFA | TSHR 4396/4885ALDH1A1 240/4885LMNA 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.